Europe’s drug regulator on June 11 identified another rare blood condition as a potential side effect of AstraZeneca’s Covid-19 vaccine and said it was looking into cases of heart inflammation after inoculation with all coronavirus shots.
Netherlands-based Mylan is buying the intellectual property and commercialization rights to Aspen Pharmacare’s thrombosis business in Europe for €641.9 million ($757.3 million).
Lonza signed a partnership agreement with Anthos Therapeutics to develop and manufacture an antibody treatment for blood clots.
On Valentine’s Day, BioSpace would be remiss not to mention, er, matters of the heart. There are reportedly 59 life sciences companies or organizations worldwide that focus on the cardiovascular system, ranging from the Aab Cardiovascular Research Institute based in West Henrietta, New York to XyloCor Therapeutics, with headquarters in Philadelphia. That number is probably low.